Chemogenetic activation of neurotensinergic neurons and projections induces hypothermia and potently excites MPO neurons.
A. I.p. injection (arrow) of CNO (20 mM, 3 µl) in NtshM3D(Gq) mice (Δ) and in Nts-cre mice (control, ●). CNO induced a hypothermia of 4.8±0.6 °C (repeated measures ANOVA, F(1,242)=21.72, p=2.8x10-6, followed by followed by Man-Whitney U tests for each time point, ** P<0.01).
B. Role of NtsR1 and NtsR2 expressed in the MPO in the CNO-induced activation of NtshM3D(Gq) neurons. NtshM3D(Gq) mice received a bilateral infusion of aCSF (gray), NtsR1 antagonist SR48692 (300 nM, 100nl, blue), NtsR2 antagonist NTRC 824 (200 nM, 100nl, black) and NtsR1 antagonist (300 nM, 100nl) + NtsR2 antagonist (200 nM, 100nl) (red) 1.5h prior to an i.p. injection of CNO (20 mM, 3 µl). The antagonists significantly reduced the hypothermia (repeated measures ANOVA, F(3,360)=71.33, p=8.82x10-16).
A,B. The points represent averages±S.D. Experiments were carried out in parallel in groups of 6
C. Chemogenetic activation of neurotensinergic neurons and neurotensinergic projections in the MPO by bath application of CNO (3 µM) in slices from NtshM3D(Gq) mice depolarizes and increases the firing rate of a MPO neuron. The firing rate increased from 0.15 Hz to 1.65 Hz.
D. Bar chart summarizing the effect of chemogenetic activation of neurotensinergic neurons and projections in the MPO on the firing rates of MPO neurons. There was a statistically significant difference between groups as determined by one-way ANOVA (F(1,16)=8.99, P=8.52x10-3; ** indicates statistical significance of P<0.01). Bars represent means ± S.D. of the normalized firing rate relative to the control. Data pooled from n=10 neurons.
E. Chemogenetic activation of neurotensinergic neurons and neurotensinergic projections in the MPO by bath application of CNO (3 µM) in slices from NtshM3D(Gq) mice increases the amplitudes and frequencies of both IPSCs and EPSCs and activates an inward current (upper trace). The NtsR1 antagonist SR48692 (100 nM) abolished the inward current activated by CNO (middle trace). The NtsR2 antagonist NTRC 824 (100 nM) did not change the inward current activated by CNO but significantly decreased the amplitude of sEPSCs (lower trace). The neuron was held at -50 mV.
F,G,H,I. Bar charts summarizing the increase in sEPSCs frequency (F) and amplitude (G) and IPSCs frequency (H) and amplitude (I). Bars represent means ± S.D. of the normalized frequency relative to the control. Data pooled from n=6 neurons. The changes were statistically significant for sEPSCs frequency (one-way ANOVA (F(3,19)=6.94, P=3.33x10-3) and amplitude (one-way ANOVA (F(3,19)=9.20, P=9.03x10-4) as well as for sIPSCs frequency (one-way ANOVA (F(3,19)=12.61, P=1.71x10-4) and amplitude (one-way ANOVA (F(3,19)=4.53, P=1.76x10-3). The P values for the inter-group comparisons are listed in Supplementary Tables 4-7.